UNSPSC 51182410: Etidronate

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C2H6O7P2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M16PXG993G, chemically known as 1,1,1-ethanetriol diphosphonate but generally known as etidronate disodium, which bears US NIH Compound Identifier 3305. European Medicines Agency schedules Etidronate disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13771MIG. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)C.

UNSPSC 51182410 Etidronate is a Commodity code covering the procurement of etidronate, a bisphosphonate pharmaceutical used to treat bone disorders, including Paget's disease and heterotopic ossification. State and local governments purchase etidronate primarily through health departments, corrections departments, public hospital systems, and Veterans Affairs–affiliated facilities. The drug is typically procured as a finished pharmaceutical product through competitive bidding processes, often bundled with broader pharmaceutical supply contracts or purchased as a specialty medication for inpatient and outpatient clinical use. Issuing bodies range from state health and human services departments managing Medicaid formularies and state prison systems to city and county hospital networks and regional health authorities.

The source provided contains no recent state and local contract opportunities under this code. Without access to active solicitation records, geographic activity and representative recent opportunities cannot be characterized. Firms pursuing etidronate supply contracts with state and local health systems should monitor health department and hospital system procurement portals, state pharmaceutical cooperative purchasing vehicles, and Medicaid managed-care RFQs and ITBs, which typically govern specialty pharmaceutical procurement at the state and local level.